Marc Pharmaceuticals (fka MPMA)

[Josh1257]

MPMA Marc Pharmaceuticals Inc. Files Form 15 To Deregister Common Stock, Class A Warrants and Class B Warrants Under the Exchange Act
Wednesday March 29, 3:25 pm ET

STAMFORD, Conn., March 29, 2006 (PRIMEZONE) -- Marc Pharmaceuticals, Inc. (OTC BB:MPMA.OB - News) (OTC BB:MPMAW.OB - News) (OTC BB:MPMAZ.OB - News) today announced that it has filed a Form 15 with the Securities and Exchange Commission (The ``SEC'') to voluntarily deregister its common stock, class A warrants and class B warrants under the Securities Exchange Act of 1934 because it has fewer than 300 holders of record. The Company will thereby cease being a ``reporting'' company.

Upon the filing of the Form 15, Marc's obligation to file certain reports with the SEC, including Forms 10-KSB, 10QSB, and 8-K, will immediately be suspended. Marc expects that the deregistration of its common stock, class A warrants and class B warrants will become effective 90 days after the date of filing the Form 15 with the SEC. The Company understands that its common stock, class A warrants and class B warrants will no longer be eligible for trading on the Over the Counter Bulletin Board (``OTCBB'') maintained by the NASD. However, the Company expects, but cannot guaranty, that its common stock, class A warrants and class B warrants will be quoted on the ``Pink Sheets'' after it ceases to be eligible for trading on the OTCBB. The Pink Sheets is a provider of pricing and financial information for the over-the-counter securities markets. It is a centralized quotation service that collects and publishes market maker quotes through its web site,http://www.pinksheets.com, which provides stock and bond pricing quotes, financial news and information about securities. There is generally more limited liquidity and more stock price volatility on the ``Pink Sheets'' as compared to the OTCBB.
Robert M. Cohen, the Company's President and CEO stated, ``After carefully considering the advantages and disadvantages of continuing as a registered company and based on management's recommendation, the Board of Directors unanimously determined to deregister the Company. In light of the dramatically increasing costs associated with being a public company, including compliance and administration burdens, our Board agrees that deregistering will result in significant expense reductions. Rather than using a great deal of our limited cash for accounting, legal and administrative expenses, this will enable management to focus more of its time and resources on the science initiatives to which the Company is dedicated. We believe this in the long run should enhance the company's value for all of our shareholders. We also hope at some point to be able to resume being a reporting company if resources permit.''
About Marc Pharmaceuticals:
Marc Pharmaceuticals is committed to identifying, developing and bringing to market, medicines and therapies that will elevate our quality of life and alleviate the suffering associated with debilitating and life threatening diseases. For more information, refer to the company Web site: http://www.marcpharmaceuticals.com.
``Safe Harbor'' statement under the Private Securities Litigation Reform Act of 1995:
Statements in this release may relate to future events or Marc's future performance. Such statements are forward-looking statements that are subject to risks and uncertainties. Investors are cautioned that such forward-looking statements are subject to inherent risks that actual results may differ materially from such forward looking statements. Risks and uncertainties include but are not limited to, (a) Marc may never obtain sufficient resources to resume as a reporting company, (b) Marc's securities may not continue to be on the ``Pink Sheets'' if there is no brokerage firm that will make a market for its securities, (c) Marc's products many not be proven to be safe or effective in humans or in animals, (d) the FDA may not approve clinical trials for Marc's products, (e) Marc may depend substantially upon the efforts of contracting parties who may not perform adequately, (f) Marc's patent rights may not be sufficient to protect its products, (g) Marc may never earn a profit from its products, (h) Marc may not be able to raise the necessary funds that are needed for the continued research and development of its products, (i) Marc's licenses require substantial performance on its part to remain effective, including the payment of substantial sums, if Marc loses a license, it will lose the right to develop and market the drug which it covers, and (j) other groups may have developed similar inventions to those of Marc, and therefore Marc may be at a competitive disadvantage.

Contact:
Marc Pharmaceuticals
Robert M. Cohen, President and CEO
203-352-8817
[e-mail]